FMS Like Tyrosine kinase 3 inhibitors Market

1
FMS Like Tyrosine kinase 3 inhibitors Market Size
Worth USD 1395.7 Million in 2030
www.emergenresearch.com
Rising incidence of Acute Myeloid Leukemia (AML)
is a key factor driving FLT3 inhibitors market
revenue growth
2
Our Model
Market Analysis
Financial Analysis
Distribution Channel Analysis
Brand Analysis
Custom Market Intelligence
Competitor Analysis
Product Analysis
Custom Research
www.emergenresearch.com
Demand Analysis
Risk Analysis
3
Business Plan Parameters
End Use Analysis
Demand Availability Analytics
Market Entry Strategy
Restructuring Revival
New Product Strategy
Product Planning / Strategy
SWOT Analysis
Marketing / Distribution Channel Feasibility
www.emergenresearch.com
Customer Identification Survey
Competitive Landscape / MA Feasibility
www.emergenresearch.com
4
Industries We Cater to
www.emergenresearch.com
5
5
Market Summary
The global FMS-Like Tyrosine kinase 3 (FLT3)
inhibitors market size was USD 405.6 Million in
2021 and is expected to register a revenue CAGR
of 14.6 during the forecast period, according to
latest analysis by Emergen Research. Rising
high-value investments for Research Development
(RD) initiatives by various major pharmaceutical
companies for improvement in therapy tolerability
and drugs is a key factor driving market revenue
growth. In addition, rising incidences of Acute
Myeloid Leukemia (AML) and relapse cases, growing
number of potential pipeline drugs, and
increasing approvals of new FLT3 inhibitor drugs
by regulatory bodies are driving revenue growth
of the FLT3 inhibitors market. According to
Novartis, AML accounts for approximately 25 of
all adult leukemia and has lowest survival rate.
FDA has now authorized three FLT3 inhibitors for
use in the U.S. Midostaurin is approved for
first-line treatment with chemotherapy, but
gilteritinib is approved for R/R disease.
Quizartinib and crenolanib are two new AML
inhibitors in late-stage development for
first-line and R/R treatment. Various advantages
of improved targeted medicines, such as increased
long-term survival rates, quality, and safety,
are driving growth of the FLT3 inhibitors market. 
www.emergenresearch.com
6
Market Summary
Some Key Highlights From the Report The
gilteritinib segment accounted for largest
revenue share in 2021 owing to continuing
clinical trials and increasing regulatory
approvals. Gilteritinib, which is a kinase
inhibitor, is recommended for people with acute
myeloid leukemia that has relapsed or become
resistant to treatment and has FLT3-TKD or
FLT3-ITD mutation. This can increase patients
survival rates, which is one of the main
requirements for getting regulatory approval. For
patients with severe, relapsing, or refractory
illness, gilteritinib is a safe,
mutation-targeted therapeutic option. A complex
pyrazine carboxamide derivative, medication also
has increased activity, selectivity, and
effectiveness against FLT3-TKD and FLT3-ITD
mutations. Type 1 FLT3 inhibitors segment
accounted for largest revenue share in 2021 owing
to increasing number of successful clinical
trials and research studies. Type 1 inhibitors
are more effective in AML cells containing either
ITD or TKD mutations as they inhibit ATP binding
in contrast to Type 2 FLT3 inhibitors. Moreover,
Type 1 FLT3 inhibitors can be used in patients
who have relapsed owing to acquired TKD
mutations, which is one of the key factors
driving revenue growth of the market. Type 1
inhibitors include midostaurin, crenolanib, and
gilteritinib. Additionally, better efficacy,
fewer side effects, and low toxicity of drugs are
major factors driving revenue growth of this
segment. Request Free Sample Copy_at_
https//www.emergenresearch.com/request-sample/130
2
www.emergenresearch.com
7
Market Summary
Emergen Research has segmented the global FLT3
inhibitors market based on drug type, therapies,
and region Drug Type Outlook (Revenue, USD
Million 2019-2030) Midostaurin Gilteritinib Soraf
enib Therapies Outlook (Revenue, USD Million
2019-2030) Type 1 FLT3 inhibitors Type 2 FLT3
inhibitors Read More _at_ https//www.emergenresearc
h.com/industry-report/fms-like-tyrosine-kinase-3-i
nhibitors-market
8
Parameter Details
Market Size Estimation Period 2020-2028
Base Year Considered 2020
Historical Data 2017-2019
Forecast Period 2021-2028
Quantitative Units Revenue in USD million CAGR from 2020 to 2028
Segments Covered Types, Application, End-Users, Regions more.
Countries Included The U.S., Germany, U.K., Italy, China, India, Japan, Brazil
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Regions Scope North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Customization Scope 10 hours of free customization expert consultation
Pricing and Purchase Options Explore Different Purchase Options Request for Discount to Avail New Year Discount
MARKET SEGMENTATION
www.emergenresearch.com
9
Regional Share Dynamics
www.emergenresearch.com
10
LATEST PUBLICATIONS
Latest published reports from the Healthcare
Sector by Emergen Research Artificial
Intelligence in Transportation Market Top
Companies https//www.emergenresearch.com/blog/to
p-10-companies-in-the-global-artificial-intelligen
ce-in-transportation-market Mobile Medical
Applications Market Top Companies
https//www.emergenresearch.com/blog/worlds-top-8
-mobile-medical-applications Tech Pouch Market
Top Companies https//www.emergenresearch.com/blo
g/top-10-best-tech-pouch-brands-in-the-world Ligh
ting  as a Service (LaaS) Market Top Companies
https//www.emergenresearch.com/blog/worlds-top-7
-leading-companies-offering-lighting-as-a-service
Tactical Data Link Market Top Companies
https//www.emergenresearch.com/blog/worlds-top-1
0-leading-companies-offering-next-level-tactical-d
ata-link-solutions  
www.emergenresearch.com
11
About Us
At Emergen Research, we believe in advancing with
technology. We are a growing market research and
strategy consulting company with an exhaustive
knowledge base of cutting-edge and potentially
market-disrupting technologies that are predicted
to become more prevalent in the coming
decade. Our expertise umbrellas the
technological environment of all major
industries, and our services help you map your
actions to ensure optimal yield. Our analysts
utilize their market proficiency to offer
actionable insights that help our clients
implement profitable strategies and optimize
their return on investment. Our services are
wide-ranging, right from technological
environment analysis to technological profiling
that highlights the existing opportunities in the
market you can capitalize on to stay ahead of
your competitors.
www.emergenresearch.com
12
Lets Talk Contact Information
Reach out to us and our Research Executives will
ensure you get the report that meets all your
requirements and address all your concerns.
14671 110 Avenue, Surrey, British Columbia, V3R2A9
www.emergenresearch.com
www.emergenresearch.com
sales_at_emergenresearch.com
1 [phone]